SPARC is a key regulator of proliferation, apoptosis and invasion in human ovarian cancer

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Chen, Jie ^a   Wang, Mei ^b   Xi, Bo ^a   Xue, Jian ^a   He, Dan ^a   Zhang, Jie ^b   Zhao, Yueran ^b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEONECTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MOUSE; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM;

ANIMALS; ANTIBODIES, NEOPLASM; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; G0 PHASE; G1 PHASE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LENTIVIRUS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; OSTEONECTIN; OVARIAN NEOPLASMS; OVARY; PEPTIDES; REPRODUCIBILITY OF RESULTS; RNA INTERFERENCE; TUMOR STEM CELL ASSAY;

EID: 84864555827     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042413     Document Type: Article

References (43)

1. Jemal A, Siegel R, Xu J, Ward E, ((2010)) Cancer statistics, 2010. CA Cancer J Clin 60(5): 277-300.
2. Bast RC Jr, Hennessy B, Mills GB, ((2009)) The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9(6): 415-428.
3. Chaffer CL, Weinberg RA, ((2011)) A perspective on cancer cell metastasis. Science 331(6024): 1559-1564.
4. Bornstein P, Sage EH, ((2002)) Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol 14(5): 608-616.
5. Tai IT, Tang MJ, ((2008)) SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist Updat 11(6): 231-246.
6. Hsiao YH, Lien HC, Hwa HL, Kuo WH, Chang KJ, et al. ((2010)) SPARC (osteonectin) in breast tumors of different histologic types and its role in the outcome of invasive ductal carcinoma. Breast J 16(3): 305-308.
7. Lien HC, Hsiao YH, Lin YS, Yao YT, Juan HF, et al. ((2007)) Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. Oncogene 26(57): 7859-7871.
8. Lau CP, Poon RT, Cheung ST, Yu WC, Fan ST, ((2006)) SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma. J Pathol 210(4): 459-468.
9. Le Bail B, Faouzi S, Boussarie L, Guirouilh J, Blanc JF, et al. ((1999)) Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma. J Pathol 189(1): 46-52.
10. Thomas R, True LD, Bassuk JA, Lange PH, Vessella RL, ((2000)) Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res 6(3): 1140-1149.
11. Chan SK, Griffith OL, Tai IT, Jones SJ, ((2008)) Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers. Cancer Epidemiol Biomarkers Prev 17(3): 543-552.
12. Wiese AH, Auer J, Lassmann S, Nährig J, Rosenberg R, et al. ((2007)) Identification of gene signatures for invasive colorectal tumor cells. Cancer Detect Prev 31(4): 282-295.
13. Brown TJ, Shaw PA, Karp X, Huynh MH, Begley H, et al. ((1999)) Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer. Gynecol Oncol 75(1): 25-33.
14. Paley PJ, Goff BA, Gown AM, Greer BE, Sage EH, ((2000)) Alterations in SPARC and VEGF immunoreactivity in epithelial ovarian cancer. Gynecol Oncol 78(3 Pt 1): 336-341.
15. Nagai MA, Gerhard R, Fregnani JH, Nonogaki S, Rierger RB, et al. ((2011)) Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients. Breast Cancer Res Treat 126(1): 1-14.
16. Koblinski JE, Kaplan-Singer BR, VanOsdol SJ, Wu M, Engbring JA, et al. ((2005)) Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis. Cancer Res 65(16): 7370-7377.
17. Atorrasagasti C, Malvicini M, Aquino JB, Alaniz L, Garcia M, et al. ((2010)) Overexpression of SPARC obliterates the in vivo tumorigenicity of human hepatocellular carcinoma cells. Int J Cancer 126(11): 2726-2740.
18. Said N, Frierson HF Jr, Chernauskas D, Conaway M, Motamed K, et al. ((2009)) The role of SPARC in the TRAMP model of prostate carcinogenesis and progression. Oncogene 28(39): 3487-3498.
19. Liang JF, Wang HK, Xiao H, Li N, Cheng CX, et al. ((2010)) Relationship and prognostic significance of SPARC and VEGF protein expression in colon cancer. J Exp Clin Cancer Res 29: 71.
20. Yang E, Kang HJ, Koh KH, Rhee H, Kim NK, et al. ((2007)) Frequent inactivation of SPARC by promoter hypermethylation in colon cancers. Int J Cancer 121(3): 567-575.
21. Yiu GK, Chan WY, Ng SW, Chan PS, Cheung KK, et al. ((2001)) SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol 159(2): 609-622.
22. Shenhua X, Lijuan Q, Hanzhou N, Xinghao N, Chihong Z, et al. ((1999)) Establishment of a highly metastatic human ovarian cancer cell line (HO-8910PM) and its characterization. J Exp Clin Cancer Res 18: 233-239.
23. Chen J, Zhang J, Zhao Y, Li J, Fu M, ((2009)) Integrin beta3 down-regulates invasive features of ovarian cancer cells in SKOV3 cell subclones. J Cancer Res Clin Oncol 135(7): 909-917.
24. Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, et al. ((2004)) Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 10(24): 8465-8471.
25. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, et al. ((1987)) A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47(12): 3239-3245.
26. Yin J, Chen G, Liu Y, Liu S, Wang P, et al. ((2010)) Downregulation of SPARC expression decreases gastric cancer cellular invasion and survival. J Exp Clin Cancer Res 29: 59.
27. Horie K, Tsuchihara M, Nakatsura T, ((2010)) Silencing of secreted protein acidic and rich in cysteine inhibits the growth of human melanoma cells with G arrest induction. Cancer Sci 101(4): 913-919.
28. Seno T, Harada H, Kohno S, Teraoka M, Inoue A, et al. ((2009)) Downregulation of SPARC expression inhibits cell migration and invasion in malignant gliomas. Int J Oncol 34(3): 707-715.
29. Zhang LQ, Jiang F, Xu L, Wang J, Bai JL, et al. ((2011)) The Role of Cyclin D1 Expression and Patient's Survival in Non-Small-Cell Lung Cancer: A Systematic Review with Meta-Analysis. Clin Lung Cancer Nov 29. Epub ahead of print.
30. Naryzhny SN, ((2008)) Proliferating cell nuclear antigen: a proteomics view. Cell Mol Life Sci 65(23): 3789-3808.
31. Liebermann DA, Hoffman B, Vesely D, ((2007)) p53 induced growth arrest versus apoptosis and its modulation by survival cytokines. Cell cycle 6: 166-170.
32. Gartel AL, ((2009)) p21 (WAF1/CIP1) and cancer: a shifting paradigm? Biofactors 35(2): 161-164.
33. Fenouille N, Robert G, Tichet M, Puissant A, Dufies M, et al. ((2011)) The p53/p21Cip1/ Waf1 pathway mediates the effects of SPARC on melanoma cell cycle progression. Pigment Cell Melanoma Res 24(1): 219-232.
34. Kelly PN, Strasser A, ((2011)) The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ 18(9): 1414-1424.
35. Fenouille N, Puissant A, Tichet M, Zimniak G, Abbe P, et al. ((2011)) SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival. Oncogene 30(49): 4887-4900.
36. Said N, Motamed K, ((2005)) Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. Am J Pathol 167(6): 1739-1752.
37. Greenaway JB, Koehler A, McCulloch CA, Petrik J, Brown TJ, et al. ((2012)) The impact of the ovarian microenvironment on the anti-tumor effect of SPARC on ovarian cancer. Biochem Cell Biol 90(1): 96-107.
38. Robert G, Gaggioli C, Bailet O, Chavey C, Abbe P, et al. ((2006)) SPARC represses E-cadherin and induces mesenchymal transition during melanoma development. Cancer Res 66(15): 7516-7523.
39. Smit DJ, Gardiner BB, Sturm RA, ((2007)) Osteonectin downregulates E-cadherin, induces osteopontin and focal adhesion kinase activity stimulating an invasive melanoma phenotype. Int J Cancer 121(12): 2653-2360.
40. Said N, Najwer I, Motamed K, ((2007)) Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer. Am J Pathol 170(3): 1054-1063.
41. Kunigal S, Gondi CS, Gujrati M, Lakka SS, Dinh DH, et al. ((2006)) SPARC-induced migration of glioblastoma cell lines via uPA-uPAR signaling and activation of small GTPase RhoA. Int J Oncol 29(6): 1349-1357.
42. McClung HM, Thomas SL, Osenkowski P, Toth M, Menon P, et al. ((2007)) SPARC Upregulates MT1-MMP Expression, MMP-2 Activation, and the Secretion and Cleavage of Galectin-3 in U87MG Glioma Cells. Neurosci Lett 419(2): 172-177.
43. Rich JN, Shi Q, Hjelmeland M, Cummings TJ, Kuan CT, et al. ((2003)) Bonerelated genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. J Biol Chem 278: 15951-15957.